Robert G Bristow
Overview
Explore the profile of Robert G Bristow including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
219
Citations
9489
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Houlahan K, Livingstone J, Fox N, Kurganovs N, Zhu H, Sietsma Penington J, et al.
J Natl Cancer Inst
. 2023 Jan;
115(4):468-472.
PMID: 36610996
Prostate cancer is one of the most heritable cancers. Hundreds of germline polymorphisms have been linked to prostate cancer diagnosis and prognosis. Polygenic risk scores can predict genetic risk of...
12.
Bhandari V, Li C, Bristow R, Boutros P
Nat Commun
. 2022 Dec;
13(1):7569.
PMID: 36481612
No abstract available.
13.
Chatzimavridou Grigoriadou V, Barraclough L, Baricevic-Jones I, Bristow R, Eden M, Haslett K, et al.
BMJ Open
. 2022 Jun;
12(6):e056600.
PMID: 35701060
Introduction: Patients receiving radiotherapy are at risk of developing radiotherapy-related insufficiency fractures, which are associated with increased morbidity and pose a significant burden to patients' quality of life and to...
14.
Burns D, Anokian E, Saunders E, Bristow R, Fraser M, Reimand J, et al.
Eur Urol
. 2022 Jun;
82(2):201-211.
PMID: 35659150
Background: Germline variants explain more than a third of prostate cancer (PrCa) risk, but very few associations have been identified between heritable factors and clinical progression. Objective: To find rare...
15.
Gillessen S, Armstrong A, Attard G, Beer T, Beltran H, Bjartell A, et al.
Eur Urol
. 2022 Apr;
82(1):115-141.
PMID: 35450732
Background: Innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but various areas of management still lack high-level evidence to inform clinical practice. The 2021...
16.
Lip H, Amini M, Zetrini A, Cai P, Abbasi A, Bristow R, et al.
Radiother Oncol
. 2022 Mar;
170:213-223.
PMID: 35227733
Introduction: Radiation therapy (RT) is a major modality for the treatment of prostate cancer (PCa), especially castration-resistant PCa (CRPC). However, hypoxia, often seen in PCa tumors, leads to radiation-resistance. This...
17.
Bristow R, Engel J, Jayasinghe I, Kampmann M, James Sansom O, Bryant D
J Cell Sci
. 2022 Feb;
135(4).
PMID: 35188214
February is LGBT+ history month, and to celebrate, Journal of Cell Science Editorial Advisory Board member David Bryant organised a conversation with a selection of scientists to explore their experiences...
18.
Livingstone J, Shiah Y, Yamaguchi T, Heisler L, Huang V, Lesurf R, et al.
Nat Commun
. 2021 Nov;
12(1):6893.
PMID: 34824250
Replicative immortality is a hallmark of cancer, and can be achieved through telomere lengthening and maintenance. Although the role of telomere length in cancer has been well studied, its association...
19.
Fraser M, Livingstone J, Wrana J, Finelli A, He H, van der Kwast T, et al.
Nat Commun
. 2021 Oct;
12(1):6248.
PMID: 34716314
Driver gene mutations that are more prevalent in metastatic, castration-resistant prostate cancer (mCRPC) than localized disease represent candidate prognostic biomarkers. We analyze 1,844 localized (1,289) or mCRPC (555) tumors and...
20.
Ali A, Du Feu A, Oliveira P, Choudhury A, Bristow R, Baena E
Nat Rev Urol
. 2021 Oct;
19(2):101-115.
PMID: 34667303
Localized prostate cancer shows great clinical, genetic and environmental heterogeneity; however, prostate cancer treatment is currently guided solely by clinical staging, serum PSA levels and histology. Increasingly, the roles of...